Comparison of Systematic, Targeted and Combined Prostate Biopsy: Our Clinical Outcomes

Basit Öğe Kaydı
dc.authoridTaşkıran, Arda Taşkın/0000-0003-4556-3475
dc.contributor.authorŞenoğlu, Yusuf
dc.contributor.authorTaşkıran, Arda Taşkın
dc.contributor.authorYüksel, Alpaslan
dc.contributor.authorBaba, Dursun
dc.date.accessioned2023-07-26T11:54:10Z
dc.date.available2023-07-26T11:54:10Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalıen_US
dc.description.abstractObjective: Our aim was to compare the diagnostic efficacy of the standard systematic, targeted and combined prostate biopsy methods in prostate cancer. Materials and Methods: Total of 161 patients who underwent prostate biopsy combined with magnetic resonance imaging-ultrasonography fusion method between August 2018 and March 2021 was evaluated retrospectively. Clinically important and insignificant cancer detection rates of biopsy results between standard, targeted and combined biopsy (CB) methods were compared. Changes in the results were also evaluated in terms of Prostate Imaging-Reporting and Data System (PIRADS) scores. Results: Prostate cancer was diagnosed in 46 (28.6%) patients by CB. Fourteen (8.7%) patients were interpreted as a clinically insignificant disease. Prostate cancer and clinically significant disease detection rates were statistically significant in favor of CB compared to targeted biopsy (TB). There was no statistically significant difference between systematic biopsy and TB results. Additionally, it was observed that cancer detection rates were higher in PIRADS o4 lesions compared to PIRADS 3 lesions in all biopsy methods. Conclusions: Our results have shown that combined prostate biopsy led to higher detection of prostate cancer and provides increased detection of clinically significant disease. High rates of clinically significant cancer, especially in patients with PIRADS o4 lesions, suggest that the PIRADS scoring is a high-level guide in detecting malignancy.en_US
dc.identifier.doi10.4274/uob.galenos.2021.2021.4.1
dc.identifier.endpage44en_US
dc.identifier.issn2147-2270
dc.identifier.issue2en_US
dc.identifier.startpage40en_US
dc.identifier.urihttps://doi.org/10.4274/uob.galenos.2021.2021.4.1
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12748
dc.identifier.volume21en_US
dc.identifier.wosWOS:000806738500002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorŞenoğlu, Yusuf
dc.institutionauthorTaşkıran, Arda Taşkın
dc.institutionauthorYüksel, Alpaslan
dc.institutionauthorBaba, Dursun
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofUroonkoloji Bulteni-Bulletin of Urooncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectProstate Cancer; Clinical Significance; Targeted Biopsy; Mri Us Fusion; Combined Biopsyen_US
dc.subjectMagnetic-Resonance; Saturation Biopsy; Cancer Detection; Fusion Biopsy; Diagnosis; Mrien_US
dc.titleComparison of Systematic, Targeted and Combined Prostate Biopsy: Our Clinical Outcomesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12748.pdf
Boyut:
126.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu